RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000131.xml
Synfacts 2020; 16(04): 0371
DOI: 10.1055/s-0040-1707632
DOI: 10.1055/s-0040-1707632
Synthesis of Natural Products and Potential Drugs
Synthesis of an Indoleamine-2,3-dioxygenase-1 (IDO1) Inhibitor
Steeneck C.
*
Kinzel O,
Anderhub S,
Hornberger M,
Pinto S,
Morschhaeuser B,
Braun F,
Kleymann G,
Hoffmann T.
Phenex Pharmaceuticals AG, Heidelberg, Germany
Discovery of Hydroxyamidine Based Inhibitors of IDO1 for Cancer Immunotherapy with Reduced Potential for Glucuronidation.
ACS Med. Chem. Lett. 2020;
11: 179-187
Discovery of Hydroxyamidine Based Inhibitors of IDO1 for Cancer Immunotherapy with Reduced Potential for Glucuronidation.
ACS Med. Chem. Lett. 2020;
11: 179-187
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
18. März 2020 (online)
Significance
Indoleamine-2,3-dioxygenase-1 (IDO1) is strongly involved in tumor immune resistance. The immune suppressive effect of IDO1 results from its capacity to degrade tryptophan to N-formylkyurenine, the first and rate-limiting step of the kyurenine pathway. The target molecule N is a low-nanomolar IDO1 inhibitor.
#
Comment
Reaction of aldoxime F with N-chlorosuccinimide (NCS) afforded N-hydroxycarbimidoyl chloride G. Treatment of G with 3-chloroaniline followed by hydroxyamidine cyclization using 1,1′-carbonyldiimidazole (CDI) and Boc deprotection afforded the key amino intermediate K.
#
#